Germany approves migraine drug Rizaport

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) and IntelGenx Corp. (TSX-V:IGX; OTCQX:IGXT) said Germany's Federal Institute for Drugs and Medical Devices (BfArM) approved Rizaport rizatriptan to treat acute migraines. It is the first marketing approval for Rizaport.

Approval was granted under the EU's decentralized procedure, with Germany serving as the reference member state. ...